Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2M5
UPID:
KLH20_HUMAN
Alternative names:
Kelch-like ECT2-interacting protein; Kelch-like protein X
Alternative UPACC:
Q9Y2M5; B3KMA0; B4DUR0; Q5TZF2; Q5ZF45; Q9H457
Background:
Kelch-like protein 20, also known as Kelch-like ECT2-interacting protein, plays a pivotal role in various cellular processes. It acts as a substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex, influencing interferon response, anterograde Golgi to endosome transport, apoptosis regulation, angiogenesis, and neurite outgrowth. This protein mediates the ubiquitination of DAPK1, leading to its degradation, and is involved in 'Lys-33'-linked ubiquitination of CORO7 and PDZ-RhoGEF/ARHGEF11.
Therapeutic significance:
Understanding the role of Kelch-like protein 20 could open doors to potential therapeutic strategies.